Subtype
Sympathetic Paraganglioma
CI-CAN-00004047Explore in graph →
Non-malignant27 active trials2 evidence items
- NCIt
- C4216
Loading cancer entity…
Subtype
CI-CAN-00004047Explore in graph →
Clinical trials
127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00049023 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors |
| completed |
| Phase 1 |
| 27 |
| O'Dorisio, M SOTHER |
| 1 |
| Jun 21, 2016 |
| clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00339131 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | completed | Phase 1 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 0 | Oct 12, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials